US 11,912,738 B2
Neuroactive steroids and their methods of use
Maria Jesus Blanco-Pillado, Arlington, MA (US); Francesco G. Salituro, Marlborough, MA (US); and Marshall Lee Morningstar, Framingham, MA (US)
Assigned to Sage Therapeutics, Inc., Cambridge, MA (US)
Filed by SAGE THERAPEUTICS, INC., Cambridge, MA (US)
Filed on Jun. 13, 2023, as Appl. No. 18/334,209.
Application 18/334,209 is a continuation of application No. 17/311,056, previously published as PCT/US2019/064692, filed on Dec. 5, 2019.
Claims priority of provisional application 62/775,470, filed on Dec. 5, 2018.
Prior Publication US 2023/0322849 A1, Oct. 12, 2023
Int. Cl. C07J 43/00 (2006.01); C07J 41/00 (2006.01)
CPC C07J 43/003 (2013.01) [C07J 41/0044 (2013.01); C07J 41/0094 (2013.01)] 17 Claims
 
1. A compound of Formula (I-l):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
each of R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, and R12 is hydrogen;
R3a is methyl;
R18 is methyl or ethyl;
R19 is hydrogen, methyl, or ethyl;
RY is methyl or cyano;
each RD is hydrogen;
q is 0, 1, 2, 3, 4, or 5; and
R55a and R55b join together with their intervening atoms to form

OG Complex Work Unit Chemistry
wherein
p is 1, and
Ra is —CN.